Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by TD Cowen analyst, Yaron Werber. Yaron Werber has given his Buy rating due ...

JPMorgan initiated coverage of Upstream Bio (UPB) with an Overweight rating and $38 price target Upsteam’s lead asset is verekitug, a recombinant human IgG1 monoclonal antibody that binds the thymic ...

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market.

Shares of Upstream Bio (UPB.O), opens new tab opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion. The robust debut ...

Oct 11 (Reuters) - Three U.S. healthcare startups priced their initial public offerings (IPO) on Thursday, including Upstream Bio (UPB.O), opens new tab which raised $255 million at a valuation of ...

Drug developer Upstream Bio Inc. expanded the size of its share sale to raise $255 million. The company, based in Waltham, Massachusetts, sold 15 million shares for $17 each, according to a ...

WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on ...

Upstream Bio (UPB), CeriBell (CBLL) and CAMP4 Therapeutics (CAMP) have set terms for their proposed initial public offerings. Upstream (UPB) said in its latest SEC filing that it was looking at ...

(Reuters) -Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion. The robust debut adds to the ...